Skip to main content

Advertisement

SpringerLink
Log in

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms that require a multidisciplinary approach for an optimal management. The lack of effectiveness of traditional DNA-damaging agents has led to the exploration of new targeted drugs in order to exploit phenotypical features of GEP-NET therapy. However, due to the orphan setting of these tumors, deeper characterization of molecular features and pathways that characterize cell growth, apoptosis, angiogenesis, and invasion are lacking, particularly genetic mutations or epigenetic alterations that generate oncogenic dependency or even addiction. The PI3K-AKT-mTOR pathway has been implicated as having a crucial role in GEP-NETs not only due to the overexpression of several growth factors and their receptors that finally activate this axis but also hereditary syndromes with constitutive activation of the mTOR pathway with high incidence of GEP-NETs. In this article, we aim to review the recent development of the main molecules that target mTOR complex and have showed promising activity in the treatment of GEPNETs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hansel, D. E., Rahman, A., Hermans, J., et al. (2003). Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Modern Pathology, 16(7), 652–659.

    Article  PubMed  Google Scholar 

  2. Zhang, J., Jia, Z., Li, Q., et al. (2007). Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer, 109(8), 1478–1486.

    Article  PubMed  CAS  Google Scholar 

  3. Furukawa, M., Raffeld, M., Mateo, C., et al. (2005). Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clinical Cancer Research, 11(9), 3233–3242.

    Article  PubMed  CAS  Google Scholar 

  4. Chaudhry, A., Papanicolaou, V., Oberg, K., et al. (1992). Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Research, 52(4), 1006–1012.

    PubMed  CAS  Google Scholar 

  5. Nilsson, O., Wangberg, B., Kolby, L., et al. (1995). Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. International Journal of Cancer, 60(5), 645–651.

    Article  CAS  Google Scholar 

  6. Fjällskog, M. L., Lejonklou, M. H., Oberg, K. E., et al. (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clinical Cancer Research, 9(4), 1469–1473.

    PubMed  Google Scholar 

  7. Wulbrand, U., Remmert, G., Zofel, P., et al. (2000). mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation, 30(8), 729–739.

    Article  PubMed  CAS  Google Scholar 

  8. Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews, 25(3), 458–511.

    Article  PubMed  CAS  Google Scholar 

  9. O’Toole, D., Couvelard, A., Rebours, V., et al. (2010). Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 17(4), 847–856.

    Article  PubMed  Google Scholar 

  10. Kolby, L., Persson, G., Franzen, S., et al. (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery, 90(6), 687–693.

    Article  PubMed  CAS  Google Scholar 

  11. Moertel, C. G., Rubin, J., & Kvols, L. K. (1989). Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. Journal of Clinical Oncology, 7(7), 865–868.

    PubMed  CAS  Google Scholar 

  12. Öberg, K., Norheim, I., Lind, E., et al. (1986). Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treatment Reports, 70(11), 1297–1304.

    PubMed  Google Scholar 

  13. Dirix, L. Y., Vermeulen, P. B., Fierens, H., et al. (1996). Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors—an antiangiogenic effect? Anti-Cancer Drugs, 7(2), 175–181.

    Article  PubMed  CAS  Google Scholar 

  14. Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.

    Article  PubMed  CAS  Google Scholar 

  15. Moertel, C. G., Lefkopoulo, M., Lipsitz, S., et al. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine, 326(8), 519–523.

    Article  PubMed  CAS  Google Scholar 

  16. Kouvaraki, M. A., Ajani, J. A., Hoff, P., et al. (2004). Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology, 22(23), 4762–4771.

    Article  PubMed  CAS  Google Scholar 

  17. Sun, W., Lipsitz, S., Catalano, P., et al. (2005). Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology, 23(22), 4897–4904.

    Article  PubMed  CAS  Google Scholar 

  18. Öberg, K., & Jelic, S. (2009). Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annals of Oncology, 20(Suppl 4), 150–153.

    PubMed  Google Scholar 

  19. Öberg, K., Kvols, L., Caplin, M., et al. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15(6), 966–973.

    Article  PubMed  Google Scholar 

  20. Capdevila, J., & Salazar, R. (2009). Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncology, 4(4), 287–296.

    Article  Google Scholar 

  21. Wullschleger, S., Loewith, R., & Hall, M. N. (2006). TOR signaling in growth and metabolism. Cell, 124(3), 471–484.

    Article  PubMed  CAS  Google Scholar 

  22. Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009). Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology, 27(13), 2278–2287.

    Article  PubMed  CAS  Google Scholar 

  23. Arcaro, A., & Guerreiro, A. S. (2007). The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Current Genomics, 8(5), 271–306.

    Article  PubMed  CAS  Google Scholar 

  24. Yuan, R., Kay, A., Berg, W. J., et al. (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology and Oncology, 2, 45.

    Article  PubMed  Google Scholar 

  25. Vignot, S., Faivre, S., Aguirre, D., et al. (2005). mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology, 16(4), 525–537.

    Article  PubMed  CAS  Google Scholar 

  26. Franke, T. F., Hornik, C. P., Segev, L., et al. (2003). PI3K/Akt and apoptosis: size matters. Oncogene, 22(56), 8983–8998.

    Article  PubMed  CAS  Google Scholar 

  27. Paez, J., & Sellers, W. R. (2003). PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treatment and Research, 115, 145–167.

    Article  PubMed  CAS  Google Scholar 

  28. LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., et al. (2008). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates, 11(1–2), 32–50.

    Article  PubMed  CAS  Google Scholar 

  29. von Wichert, G., Jehle, P. M., Hoeflich, A., et al. (2000). Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research, 60(16), 4573–4581.

    Google Scholar 

  30. Van Gompel, J. J., & Chen, H. (2004). Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery, 136(6), 1297–1302.

    Article  PubMed  Google Scholar 

  31. Zatelli, M. C., Minoia, M., Martini, C., et al. (2010). Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocrine-Related Cancer, 17(3), 719–729.

    Article  PubMed  CAS  Google Scholar 

  32. Tee, A. R., Fingar, D. C., Manning, B. D., et al. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13571–13576.

    Article  PubMed  CAS  Google Scholar 

  33. Verhoef, S., van Diemen-Steenvoorde, R., Akkersdijk, W. L., et al. (1999). Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. European Journal of Pediatrics, 158(4), 284–287.

    Article  PubMed  CAS  Google Scholar 

  34. Eledrisi, M. S., Stuart, C. A., & Alshanti, M. (2002). Insulinoma in a patient with tuberous sclerosis: Is there an association? Endocrine Practice, 8(2), 109–112.

    PubMed  Google Scholar 

  35. Dworakowska, D., & Grossman, A. B. (2009). Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocrine-Related Cancer, 16(1), 45–58.

    Article  PubMed  CAS  Google Scholar 

  36. Hattori, S., Maekawa, M., & Nakamura, S. (1992). Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21. Oncogene, 7(3), 481–485.

    PubMed  CAS  Google Scholar 

  37. Johannessen, C. M., Reczek, E. E., James, M. F., et al. (2005). The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America, 102(24), 8573–8578.

    Article  PubMed  CAS  Google Scholar 

  38. Blansfield, J. A., Choyke, L., Morita, S. Y., et al. (2007). Clinical, genetic and radiographic analysis of 108 patients with von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery, 142(6), 814–818. discussion 818 e1–2.

    Article  PubMed  Google Scholar 

  39. Forsythe, J. A., Jiang, B. H., Iyer, N. V., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology, 16(9), 4604–4613.

    PubMed  CAS  Google Scholar 

  40. Woodward, E. R., & Maher, E. R. (2006). Von Hippel–Lindau disease and endocrine tumour susceptibility. Endocrine-Related Cancer, 13(2), 415–425.

    Article  PubMed  CAS  Google Scholar 

  41. Thakker, R. V. (2010). Multiple endocrine neoplasia type 1 (MEN1). Best Practice & Research. Clinical Endocrinology & Metabolism, 24(3), 355–370.

    Article  CAS  Google Scholar 

  42. Debelenko, L. V., Zhuang, Z., Emmert-Buck, M. R., et al. (1997). Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Research, 57(11), 2238–2243.

    PubMed  CAS  Google Scholar 

  43. Jakobovitz, O., Nass, D., DeMarco, L., et al. (1996). Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. The Journal of Clinical Endocrinology and Metabolism, 81(9), 3164–3167.

    Article  PubMed  CAS  Google Scholar 

  44. Öberg, K. (2009). Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Current Opinion in Endocrinology, Diabetes and Obesity, 16(1), 72–78.

    Article  Google Scholar 

  45. Wang, E. H., Ebrahimi, S. A., Wu, A. Y., et al. (1998). Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Research, 58(19), 4417–4420.

    PubMed  CAS  Google Scholar 

  46. Missiaglia, E., Dalai, I., Barbi, S., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28(2), 245–255.

    Article  PubMed  CAS  Google Scholar 

  47. Temsirolimus (Torisel®) (2010). Full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022088s008lbl.pdf. Accessed 13 Oct 2010.

  48. Durán, I., Kortmansky, J., Singh, D., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95(9), 1148–1154.

    Article  PubMed  Google Scholar 

  49. Everolimus (Afinitor®) (2010). Full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s004lbl.pdf. Accessed 13 Oct 2010.

  50. Zitzmann, K., De Toni, E. N., Brand, S., et al. (2007). The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 85(1), 54–60.

    Article  PubMed  CAS  Google Scholar 

  51. Tabernero, J., Rojo, F., Calvo, E., et al. (2008). Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology, 26(10), 1603–1610.

    Article  PubMed  CAS  Google Scholar 

  52. Yao, J. C., Phan, A. T., Chang, D. Z., et al. (2008). Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology, 26(26), 4311–4318.

    Article  PubMed  Google Scholar 

  53. Yao, J. C., Lombard-Bohas, C., Baudin, E., et al. (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology, 28(1), 69–76.

    Article  PubMed  CAS  Google Scholar 

  54. Pavel, M., Hainsworth, J.D., Baudin, E., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus plus octreotide LAR vs ersus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). In: 35th European Medical Oncology Society; 2010; Milan, Italy.

  55. Yao, J.C., Shah, M.H., Ito, T., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). In: 35th European Society Medical Oncology; 2010; Milan, Italy

Download references

Acknowledgements

The author acknowledges Dr. Ximena Alvira from HealthCo, SL (Madrid, Spain) for her assistance in the preparation of this manuscript and Pfizer Spain for the financial support of medical writing services.

Conflicts of interest

The authors declare that they do not have any conflict of interest that may inappropriately influence this work.

Author information

Authors and Affiliations

  1. Medical Oncology Department, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

    Jaume Capdevila

  2. Medical Oncology Department, University ICO-Duran i Reynals, Barcelona, Spain

    Ramón Salazar

  3. Endocrinology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain

    Irene Halperín

  4. Medical Oncology Department, University Hospital ICO-Germans Trias I Pujol, Barcelona, Spain

    Albert Abad

  5. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

    James C. Yao

Authors
  1. Jaume Capdevila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramón Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Halperín
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert Abad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James C. Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaume Capdevila.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Capdevila, J., Salazar, R., Halperín, I. et al. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 30 (Suppl 1), 27–34 (2011). https://doi.org/10.1007/s10555-011-9290-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-011-9290-3

Keywords

Search

Navigation